Table 2 Pathologic features of the resected specimens

From: A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer

Variable No. of patients ( n =67) (%)
Tumour differentiation
Well/median differentiated 4 (6.0)
Poorly differentiated/mucinous or signet ring cell carcinoma 63 (94.0)
Lauren classification
Intestinal 23 (34.3)
Diffuse 37 (55.2)
Mixed (intestinal+diffuse) 7 (10.4)
Local infiltration
Yes 4 (6.0)
No 63 (94.0)
Neural invasion
Yes 0
No 67 (100)
Vascular invasion
Yes 8 (11.9)
No 59 (88.0)
ypT stage
T0 2 (3.0)
T1 2 (3.0)
T2 15 (22.4)
T3 29 (43.3)
T4a 15 (22.4)
T4b 4 (6.0)
ypN stage
N0 31 (46.3)
N1 9 (13.4)
N2 9 (13.4)
N3a 11 (16.4)
N3b 7 (10.4)
ypTNM
0 2 (3.0)
I 9 (13.4)
II 30 (44.7)
III 26 (38.8)
Pathological evaluation standard of JCGC
G3 2 (3.0)
G2 18 (26.9)
G1b 23 (34.3)
G1a 24 (35.8)
G0 0
Becker score
90% 15 (22.4)
<90% 52 (77.6)
Graded histologic response
50% 33 (49.2)
<50% 34 (50.7)
  1. Abbreviation: JCGC=Japanese classification of Gastric Cancer.